1.Epidemiological characteristics and disease burden of liver cancer in Guangdong Province
Ying ZHANG ; Yixuan CHEN ; Rong CAO ; Yue GAO ; Yutong HAN ; Ye WANG ; Ruilin MENG ; Xueyan ZHENG ; Yu LIAO ; Zhuanping ZENG
Journal of Public Health and Preventive Medicine 2026;37(1):68-72
Objective To analyze the epidemiological characteristics and disease burden of liver cancer in Guangdong Province in 2020, and to provide a scientific foundation for the development of regionalized prevention and control strategies for liver cancer. Methods According to the cancer registry data of Guangdong Province, the incidence, mortality and age-standardized rate by Chinese standard population in 2020 were calculated to analyze the epidemiological characteristics of liver cancer. The disability adjusted life years (DALYs), year of life loss (YLL), year of lived with disability (YLD), and cause-eliminated life expectancy were used to assess the disease burden of liver cancer. Results In 2020, the crude incidence rate and the age-standardized incidence rate of liver cancer in Guangdong Province were 27.79/100 000 and 20.84/100 000,respectively, and the crude mortality rate and the age-standardized mortality rate of liver cancer were 25.49/100,000 and 17.64/100 000, respectively. The total DALY and DALY rate of liver cancer in Guangdong Province were 515 311 person-years and 513.83/100 000, respectively. After eliminating the causes of death from liver cancer, the life expectancy in Guangdong Province increased from 84.60 years to 84.99 years. All indicators consistently demonstrated that the burden of liver cancer was higher in males than that in females, and the burden of liver cancer was higher in rural areas than that in urban areas. Conclusion Liver cancer in Guangdong Province exhibits a high incidence, mortality and disease burden level in 2020. There are obvious differences of gender, age and region in cancer burden. It is necessary to strengthen liver cancer screening and diagnosis and treatment in men, the elderly and those in rural areas to reduce the burden of liver cancer gradually in Guangdong Province.
2.Clinical phenotype and genotypic analysis of a four-generation Chinese pedigree affected with Stickler syndrome and a literature review.
Wenjun HE ; Fang TANG ; Fan JIANG ; Ziman CHEN ; Yan LU ; Yutong NI ; Jianying ZHOU ; Dongzhi LI
Chinese Journal of Medical Genetics 2025;42(6):684-690
OBJECTIVE:
To carry out genetic testing and clinical phenotypic characterization on a four-generation Chinese pedigree affected with Stickler syndrome type I and explore its genotype-phenotype correlation.
METHODS:
A child presented at the Second Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine in February 2023 for micrognathia, glossoptosis and cleft palate and his family members were selected as the study subjects. Clinical data were collected from the affected members, and peripheral blood samples were obtained from 17 participants (including 4 patients and 13 asymptomatic individuals). Whole exome sequencing (WES) was carried out. Candidate variant was verified by Sanger sequencing. Genotype-phenotype correlation was analyzed by integrating the sequencing data with evidence from existing literature. This study has bee granted by the Ethics Committee of Guangdong Provincial Hospital of Traditional Chinese Medicine and Guangzhou Women and Children's Medical Center (Ethics No.: 2022-406B00).
RESULTS:
The four-generation pedigree has comprised 19 members. In addition to the proband, 5 affected individuals had manifested with high myopia, congenital cataracts, and progressive vision loss. Two deceased members reportedly exhibited similar ocular manifestations. Among the four living patients, two had developed retinal detachment, while two others presented with chronic joint pain onset between 35 ~ 40 years of age. One patient required hip replacement surgery at age 42 secondary to femoral head necrosis. The proband, the youngest affected member, exhibited characteristic phenotypes including congenital micrognathia and cleft palate, consistent with Pierre-Robin syndrome. Genetic analysis revealed a heterozygous nonsense mutation in COL2A1 (NM_001844.5: c.2668C>T; p.Gln890Ter) segregating with the disease in all four symptomatic patients. This variant was absent in asymptomatic family members and unaffected controls. While the mutation is listed in ClinVar, no clinical case report has associated it with this phenotypic spectrum. It was not recorded in population databases (gnomAD v4.1.0, 1000 Genomes Project, or ExAC), supporting its potential pathogenicity.
CONCLUSION
This study has diagnosed a four-generation Chinese pedigree with Stickler syndrome type I attributed to the pathogenic COL2A1 variant c.2668C>T (p.Gln890Ter), which is a rare nonsense mutation associated with ocular predominance and variable skeletal involvement. Notably, this family exhibited marked clinical heterogeneity despite sharing the identical genotype, which highlighted the challenges in phenotype-genotype correlation. The autosomal dominant transmission pattern observed in this pedigree has provided critical insights into COL2A1-related collagenopathies and underscored the necessity of ultrasonographic monitoring for ocular anomalies during prenatal diagnosis. Above findings have advanced our understanding of the pleiotropic effects in type Ⅱ collagen disorders and laid the foundation for precision-based genetic counseling, enabling targeted cascade screening and implementation of tertiary prevention strategies against congenital disabilities for high-risk families.
Adolescent
;
Adult
;
Child
;
Child, Preschool
;
Female
;
Humans
;
Male
;
Middle Aged
;
Arthritis/genetics*
;
Collagen Type II/genetics*
;
Connective Tissue Diseases/genetics*
;
Exome Sequencing
;
Genetic Association Studies
;
Genotype
;
Hearing Loss, Sensorineural/genetics*
;
Mutation
;
Pedigree
;
Phenotype
;
Retinal Detachment/genetics*
;
East Asian People/genetics*
3.Analysis of efficacy and prognostic factors of fractionated stereotactic radiotherapy (FSRT) for brain metastases in 52 breast cancer patients
Hu CHEN ; Yutong TAN ; Yasha MU ; Xiaoyong XIANG ; Yuexin YANG ; Lingling FENG ; Xiaoye SU ; Wenjue ZHANG ; Gang XU ; Jing JIN
Chinese Journal of Radiation Oncology 2025;34(3):256-264
Objective:To analyze the efficacy and prognostic factors of fractionated stereotactic radiotherapy (FSRT) for patients with breast cancer brain metastases (BCBM).Methods:Medical records and follow-up data of BCBM patients who underwent FSRT in Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center and Shenzhen People's Hospital from August 2019 to May 2023 were collected. The R Studio platform of the R version 4.2.1 statistical software was applied to analyze patients' baseline characteristics, 1- and 2-year local brain control (LBC), overall survival (OS) and distant brain control (DBC) and corresponding median failure-free survival, draw survival curve using Kaplan-Meier method. Prognostic factors were screened by univariate analysis and multivariate analysis (Cox regression).Results:Cumulatively, 52 patients (163 metastases in total) had a median survival follow-up of 22.1 months, 83% were<60 years old. Molecular typing: 13 cases (25%) were positive for human epidermal growth factor receptor 2 (HER2+) / hormone receptor negative (HR-), 2 cases (4%) were luminal A, 26 cases (50%) were luminal B, and 11 cases (21%) were triple negative. The median number of brain metastases was 2 (range: 1 - 17). Follow-up outcomes: the median OS was 34.0 months, with 1- and 2-year OS rates of 85.6% and 65.4%, respectively; the median LBC was 20.6 months, with 1- and 2-year LBC rates of 79.2% and 45.2%, respectively; and the median DBC was 10.3 months, with 1- and 2-year DBC rates of 46.7% and 28.9%, respectively. During follow-up, 13 patients underwent salvage local therapy (10 FSRT); 5 developed radiation necrosis (1 symptomatic). Prognostic factor analysis: absence of extracranial organ metastases (compared with ≥3) was a protective factor for OS, P<0.05. For LBC, fewer (1 - 2) extracranial organ metastases (compared with ≥3), and single brain metastasis (compared with ≥2) were favorable prognostic factors , while N 3 staging upon initial diagnosis was a poor prognostic factor (all P<0.05). For DBC, brain metastasis after surgery was a good prognostic factor, while complicated with lung metastasis and asymptomatic brain metastasis at the first diagnosis were poor prognostic factors (all P<0.05). Conclusions:FSRT yields relatively good LBC and poor DBC for BCBM patients. A certain percentage of patients require salvage FSRT during follow-up, but OS is maintained acceptable and the radiation necrosis is tolerable. Among the prognostic factors, the absence of extracranial metastatic organs is a good prognostic factor for OS; patients with single brain metastasis, fewer extracranial metastatic organs, and non-N 3 staging upon initial diagnosis can obtain better LBC after FSRT.
4.Expert consensus on liquid biopsy-based multi-cancer early detection (2025 edition)
Wanqing CHEN ; Kexin CHEN ; Yutong HE ; Weihua JIA ; Zhihua LIU ; Hongxia MA ; Xiaoping MIAO ; Kaifeng PAN ; Chen WU ; Changfa XIA ; Jinliang XING ; Yongjie XU
Chinese Journal of Oncology 2025;47(7):558-574
Cancer stands as a significant global public health challenge, and cancer screening serves as a pivotal strategy for reducing its mortality. Presently, only a limited number of cancer types have appropriate screening methods available. Traditional single-cancer screening approaches are fraught with limitations, including invasiveness, low accuracy, and poor patient compliance. Multi-cancer early detection (MCED) leveraging liquid biopsy technology enables non-invasive and efficient early detection of multiple cancers by analyzing biomarkers such as cell-free DNA, cell-free RNA, proteins, and metabolites in blood and other bodily fluids. This innovative approach substantially broadens the spectrum of detectable cancers and enhances population coverage, showcasing immense potential for improving existing cancer screening strategies. This expert consensus comprehensively reviews the progress of liquid biopsy-based MCED, biomarker selection and detection technologies, the criteria for cancer type selection, research design and clinical utility evaluation, as well as implementation pathways. The overarching goal of this consensus is to offer scientific guidance for further research and the widespread adoption of MCED, thereby facilitating the continuous optimization of cancer screening strategies.
5.Serum KL-6 expression in anti-MDA5-positive juvenile dermatomyositis with interstitial lung disease
Yutong GAO ; Tianping CHEN ; Peng HU
Chongqing Medicine 2025;54(3):593-596
Objective To investigate the expression of Krebs Von den Lungen-6(KL-6)in serum of children with anti-melanoma differentiation associated gene 5(MDA5)positive juvenile dermatomyositis(JDM)complicated with interstitial lung disease(ILD)and its clinical significance.Methods Thirty children with anti-MDA5-positive JDM who were admitted to the rheumatology Department of Anhui Children's Hos-pital from January 2020 to December 2023 were selected as the study objects.The children were divided into the ILD group(n=15)and the non-ILD group(n=15)according to whether they had concurrent ILD.Then,the subjects with rapid progressive interstitial lung disease(RP-ILD)in the ILD group were classified as the RP-ILD group(n=5).The expression level of serum KL-6 was detected by chemiluminescence method,and the difference of KL-6 level among the three groups was analyzed,as well as the correlation with clinical indi-cators.Results The level of KL-6 in the RP-ILD group was higher than that in the ILD group(n=10)and the non-ILD group[1 345.22(988.40,1 744.20)U/mL vs.578.00(441.50,845.50)U/mL vs.278.23(145.50,345.20)U/mL],the difference was statistically significant(P<0.05).The level of KL-6 in the ILD group(n=15)after treatment was significantly lower than that before treatment[(323.89±134.19)U/mL vs.(825.12±320.02)U/mL],the difference was statistically significant(P<0.05).There was a positive correlation between KL-6 level and serum ferritin level(P<0.05).Conclusion KL-6 was highly expressed in serum of anti-MDA5 positive JDM children complicated with ILD.
6.Impact of daily diet on military training injuries among high-altitude officers and soldiers
Yutong DONG ; Maolin YANG ; Yangkai ZHANG ; Junjiang YANG ; Xiaobo LI ; Mo LI ; Chen ZHANG ; Yan RUAN ; Junlei ZHANG ; Yan HU
Journal of Army Medical University 2025;47(1):30-37
Objective To explore the characteristics of military training injuries in high-altitude troops and determine the possible impact of daily diet on these training injuries in order to provide theoretical reference for scientific training and medical service support for high-altitude troops.Methods A cross-sectional scheme was adopted in this study.A self-designed Military Training Injury Questionnaire for Plateau Troops was used to survey the officers and soldiers from resident high-altitude troops in July 2024 for their training injuries,daily diet,and other situations.The obtained data were statistically analyzed.Results Among the 3 655 participants,the incidence of military training injuries was 17.87%.The subject with highest incidence was physical training(45.94%),the most common season was winter(31.39%).The most common sites of injury were waist(28.48%),knees(22.21%),and ankles(18.07%),and the most common types were sprains(28.48%),chronic fatigue injuries(18.38%)and strains(12.25%).The intake amounts of coarse grains and potatoes,bean products,aquatic products and nuts were relatively low in the daily diet of high-altitude troops.Multivariate logistic regression analysis found intake of fruit(OR=0.625,95%CI:0.508~0.768,P<0.001)and of nut(OR=0.759,95%CI:0.654~0.879,P<0.001)were correlated with the occurrence of training injury.Conclusion The occurrence pattern of military training injuries in high-altitude troops in this survey is basically consistent with that of previous reports,but the incidence rate is slightly decreased.Regular consumption of fruit and nut may be protective factors for the occurrence of training injuries.
7.Investigation on the current status of health insurance CHS-DRG/DIP performance evaluation of hospitals in China
Yutong WANG ; Xiaokun LIU ; Xueqin SUN ; Wei ZHANG ; Wenting ZHENG ; Chen XIE ; Rui DONG ; Weiguo ZHU ; Ding HAN
Chinese Journal of Hospital Administration 2025;41(1):55-62
Objective:To investigate the current status of implementing medical insurance performance evaluation in the hospitals of China under the background of China Healthcare Security Diagnosis Related Groups (CHS-DRG) and Diagnosis-Intervention Packet (DIP) payment reform, explore the perspectives and recommendations of key department leaders (e.g., health insurance, medical affairs, pricing, and performance evaluation departments) regarding health insurance performance evaluation, analyze the influencing factors in its implementation, so as to provide references for hospitals to develop and refine health insurance performance evaluation strategies.Methods:A questionnaire was designed and distributed to hospitals across 31 provincial-level administrative regions in China from December 1 to 31, 2023. The survey targeted secondary and tertiary general or specialized hospitals. The main responsible persons from four functional departments, including medical insurance, healthcare, pricing, and performance, were invited to participate in the survey. Descriptive analysis was conducted on the questionnaire data, and the chi-square test was used for differential analysis of unordered categorical variables, while the Wilcoxon rank sum test was used for differential analysis of ordered categorical variables.Results:A total of 761 valid questionnaires were collected. Most respondents were health insurance department leaders (420, 55.19%). Among them, 741 respondents reported that their hospitals used CHS-DRG or DIP payment, with 258 indicating that their hospitals had already developed and implemented health insurance performance evaluation plans. A majority (685, 90.01%) expressed support for such initiatives. Influencing factor analysis revealed that hospital type, level, scope of health insurance management departments, and payment methods might impact the implementation of health insurance performance evaluation ( P<0.05). Conclusions:Few hospitals have currently adopted health insurance performance evaluation, underscoring the urgency to establish a scientific and reasonable evaluation plan as a robust tool for internal hospital management.
8.Relationship between high-density lipoprotein subfraction cholesterol and their subtypes with coronary heart disease and disease progression
Yutong WU ; Shaoyi LIN ; Wei HU ; Weifeng XU ; Shenghuang WANG ; Xiaomin CHEN
Chinese Journal of Laboratory Medicine 2025;48(7):888-894
Objective:To investigate the impact of high-density lipoprotein (HDL) subfraction cholesterol, measured by the vertical auto profile (VAP) technique based on vertical density gradient ultracentrifugation, on the occurrence and progression of coronary heart disease.Methods:This retrospective case-control study consecutively enrolled 94 inpatients diagnosed with coronary artery disease (CAD) by percutaneous coronary angiography at Ningbo University Affiliated First Hospital between June 2023 and June 2024 (CAD group), and 48 outpatients from the cardiology department without carotid or coronary atherosclerosis(non-CAD group). The VAP technique was employed to measure HDL subfraction cholesterol levels (HDL 3-C and HDL 2-C) and their subtypes (HDL 2a-C, HDL 2b-C, HDL 2c-C; HDL 3a-C, HDL 3b-C, HDL 3c-C, HDL 3d-C). Logistic regression analysis was performed to assess the association between HDL subfraction composition and CAD. CAD patients were further stratified by the number of affected coronary vessels (left anterior descending artery, left circumflex artery, and right coronary artery): 44 with single-vessel disease, 22 with double-vessel disease, and 28 with triple-vessel disease for correlation analysis. All CAD patients underwent 6-month clinical and telephone follow-up to record major adverse cardiovascular events (MACE), including acute myocardial infarction, stroke, and repeat revascularization. Using the median HDL 3d-C level (0.064 mmol/L) as cutoff, CAD patients were divided into high-level ( n=48) and low-level ( n=46) subgroups for Kaplan-Meier survival analysis with log-rank testing. Results:Compared with non-CAD controls, CAD patients showed significantly higher HDL 3d-C [0.064 (0.041, 0.095) mmol/L vs 0.055 (0.038, 0.067) mmol/L] and HDL 3b-C [0.031 (0.001, 0.054) mmol/L vs 0.007 (0.004, 0.029) mmol/L], lower HDL 3c-C (0.220±0.080 mmol/L vs 0.254±0.062 mmol/L) and HDL 3a-C [0.282 (0.224, 0.351) mmol/L vs 0.334 (0.269, 0.433) mmol/L] (all P<0.05). Logistic regression revealed that HDL2b-C was a protective factor against atherosclerosis severity ( OR=0.914, 95% CI 0.896-0.987, P<0.001); HDL 3d-C served as both a CAD risk factor ( OR=2.303,95% CI 1.740-3.047, P<0.001) and disease progression indicator ( OR=1.224, 95% CI 1.123-1.335, P=0.025). MACE patients ( n=6) had elevated HDL3d-C versus non-MACE cases ( n=88) [0.120 (0.083, 0.173) mmol/L vs 0.061 (0.037, 0.092) mmol/L, P<0.05]. The high HDL 3d-C subgroup demonstrated significantly lower 6-month survival (χ2=4.777, P=0.029). Conclusion:Contrary to conventional understanding, our study reveals that HDL2b serves as a protective factor against coronary artery disease progression, whereas HDL 3d-C acts not only as a pathogenic factor for CAD but also as a critical determinant of CAD-related adverse events.
9.Value of fully autonomous ultrasonic robot in spleen imaging
Xuejuan WANG ; Yingying CHEN ; Xianghui CHEN ; Xuan ZHANG ; Xiuzhu MA ; Yun ZHANG ; Yutong MA ; Sufang LAI ; Nong GAO ; Haiyan KOU ; Shaohua ZHANG ; Faqin LYU
Chinese Journal of Ultrasonography 2025;34(5):426-430
Objective:To investigate the clinical value of a fully autonomous ultrasound robot in splenic ultrasound imaging.Methods:A retrospective study was conducted by enrolling 56 adult volunteers from the Third Medical Center of the Chinese PLA General Hospital between February 1-8,2024 as research subjects.A senior physician sequentially performed splenic ultrasound examinations using both the fully autonomous ultrasound robot and a matched portable ultrasound device. The acquired images were randomly coded and scored via a double-blind method by 3 physicians. The differences of the image quality scores and high-quality image proportions between the two groups were compared. Examination durations were recorded and compared between the two groups.Results:Both modalities successfully acquired splenic images in all 56 volunteers. No statistically significant differences were observed in image quality scores among the 3 physicians:(3.52 ± 1.31)points vs.(3.83 ± 1.23)points,(2.77 ± 1.23)points vs.(3.17 ± 1.17)points,and(3.48 ± 0.97)points vs.(3.79 ± 0.94)points(all P>0.05). The numbers of images scoring ≥ 3 points showed no significant differences:45(80.36%) vs. 50(89.29%),30(53.57%) vs. 38(67.86%),and 48(85.71%) vs. 52(92.86%)(all P>0.05). The fully autonomous ultrasound robot required significantly longer examination time[(60.86 ± 50.55)s vs.(7.95 ± 4.35)s, t=6.88, P<0.01]. Conclusions:The fully autonomous ultrasound robot demonstrates comparable image quality and clinically acceptable image proportions to conventional portable ultrasound in splenic examinations. These findings suggest its potential equivalence to operator-dependent ultrasound for splenic imaging,supporting its feasibility as an alternative ultrasound modality despite longer procedural duration.
10.Experimental study on the inhibitory effects of anlotinib on thyroid cancer progression and its induction of redifferentiation
Yutong XU ; Jiang WU ; Jun CHEN ; Bo LUO ; Feng WANG ; Jun ZHANG
Chinese Journal of Nuclear Medicine and Molecular Imaging 2025;45(4):229-233
Objective:To explore the effects of anlotinib on the proliferation, apoptosis, and migration of thyroid cancer cells, and investigate its role in inducing redifferentiation and enhancing iodine uptake capacity, providing a preliminary evaluation of its efficacy in tumor treatment.Methods:(1)The cell proliferation was detected by cell counting kit-8 (CCK-8) assay, and different concentrations (0, 1/4 half maximal inhibitory concentration (IC 50), 1/2IC 50, IC 50) of anlotinib were used to treat CAL62 and FTC133 thyroid cancer cells for 24h. The clonogenic formation experiment, cellular activity and drug toxicity staining, scratch healing assay, and apoptosis in situ fluorescence staining were employed to assess cell clonogenicity, apoptosis, and migration abilities. (2) CAL62 and FTC133 cells were treated with various concentrations of anlotinib, and changes in the expression levels of iodine metabolism-related proteins (sodium/iodide symporter (NIS), thyroid peroxidase (TPO), and thyroid-stimulating hormone receptor (TSHR)) were detected using Western blot. (3) Iodine uptake experiments were conducted to observe changes in the iodine uptake functionality of thyroid cancer cells following treatment with different concentrations of anlotinib for 24 h. (4) The thyroid cancer xenograft nude mouse models were established and divided into control group (physiological saline), low-dose group (1mg/kg), medium-dose group (2mg/kg), and high-dose group (4mg/kg). Mice were treated with varying doses of the drug, the therapeutic effects and the changes in iodine harvesting function on tumors were evaluated. One-way analysis of variance was used for comparison among groups. Results:Anlotinib treatment resulted in significantly reduced cell viability, decreased clonogenic formation, increased apoptosis rates, and reduced scratch healing rates in CAL62 and FTC133 cells ( F values: 53.75-211.90, all P<0.001). After anlotinib treatment, the levels of iodine metabolism-related proteins (NIS, TPO and TSHR) significantly increased ( F values: 21.14-710.00, all P<0.001), and iodine uptake rates in thyroid cancer cells also increased significantly ( F values: 36.45, 32.34, both P<0.001). The nude mouse treatment experiment showed tumor growth in the anlotinib treatment group was inhibited, and tumors iodine uptake rates were increased, both were statistically significant ( F values: 74.09, 38.22, both P<0.001). Conclusions:Anlotinib can inhibit thyroid cancer proliferation and growth, promote apoptosis, reduce cell migration capabilities, induce thyroid cancer cells redifferentiation, and enhance iodine uptake capacity. Anlotinib can induce the redifferentiation of thyroid cancer at the animal level and has better efficacy.


Result Analysis
Print
Save
E-mail